- Galli, Flavia
- Forin, Edoardo
- Motos, Ana
- Molina Saldarriaga, Francisco José
- Gabarrús, Albert
- Canseco, Joan
- Fernández Barat, Laia
- Barbeta, Enric
- Calabretta, Davide
- Ceccato, Adrián
- Bermejo Martín, Jesús Francisco
- Ferrer, Ricard
- Riera, Jordi
- Peñuelas, Oscar
- Lorente, José Ángel
- Gonzalo Calvo, David de
- Menéndez, Rosario
- González, Jessica
- Palomeque, Andrea
- Soler Comas, Alba
- Amaya Villar, Rosario
- Anon, José Manuel
- Balan Mariño, Ana
- Barberà, Carme
- Barberán, José
- Blandino Ortiz, Aaron Rolando
- Bustamante Munguira, Elena
- Caballero, Jesús
- Cantón Bulnes, María Luisa
- Carbajales Pérez, Cristina
- Carbonell, Nieves
- Catalán González, Mercedes
- Frutos, Raúl de
- Franco, Nieves
- Galbán, Cristóbal
- López Lago, Ana
- Gumucio Sanguino, Víctor D.
- Torre, María del Carmen de la
- Díaz, Emilio
- Estella, Ángel
- Gallego Curto, Elena
- García Garmendia, José Luis
- Gómez, José Manuel
- Huerta, Arturo
- Jorge García, Ruth Noemí
- Loza Vázquez, Ana
- Marín Corral, Judith
- Martín Delgado, María Cruz
- Martínez de la Gándara, Amalia
- Martínez Varela, Ignacio
- López Messa, Juan
- Albaiceta, Guillermo M.
- Andrea Novo, Mariana
- Peñasco, Yhivian
- Pérez García, Felipe|||0000-0002-4885-4334
- Pozo Laderas, Juan Carlos
- Ricart, Pilar
- Sagredo, Víctor
- Sánchez Miralles, Ángel
- Sancho Chinesta, Susana
- Roche Campo, Ferran
- Socias Crespí, Lorenzo
- Solé Violan, Jordi
- Suarez Sipmann, Fernando
- Tamayo Lomas, Luis
- Trenado, José
- Úbeda, Alejandro
- Valdivia, Luis Jorge
- Vidal, Pablo
- Boado, María Victoria
- Rodriguez, Alejandro
- Ferrer, Miquel
- Barbé, Ferran
- Torres, Antoni
- CIBERESUCICOVID Project investigators
CIBERESUCICOVID Project investigators (COV20/00110, ISCIII): Rafael Mañez, Felipe Rodríguez de Castro, María Mora Aznar, Mateu Torres, María Martinez, Cynthia Alegre, Sofía Contreras, Javier Trujillano, Montse Vallverdú, Miguel León, Mariona Badía, Begoña Balsera, Lluís Servià, Judit Vilanova, Silvia Rodríguez, Neus Montserrat, Silvia Iglesias, Javier Prados, Sula Carvalho, Mar Miralbés, Josman Monclou, Gabriel Jiménez, Jordi Codina, Estela Val, Pablo Pagliarani, Jorge Rubio, Dulce Morales, Andrés Pujol, Àngels Furro, Beatriz García, Gerard Torres, Javier Vengoechea, Silvia Gomez, Lorena Forcelledo Espina, Emilio García Prieto, Paula Martín Vicente, Cecilia Del Busto Martínez, María Aguilar Cabello, Carmen Eulalia Martínez Fernández, María Luisa Blasco Cortés, Ainhoa Serrano Lázaro, Mar Juan Díaz, María Teresa Bouza Vieiro, Inés Esmorís Arijón, David Campi Hermoso, Rafaela Nogueras Salinas, Teresa Farre Monjo, Ramon Nogue Bou, Gregorio Marco Naya, Núria Ramon Coll, Juan Carlos Montejo-González, Gloria Renedo Sanchez-Giron, Juan Bustamante-Munguira, Ramon Cicuendez Avila, Nuria Mamolar Herrera, Alexander Agrifoglio, Lucia Cachafeiro, Emilio Maseda, Albert Figueras, Maria Teresa Janer, Laura Soliva, Marta Ocón, Luisa Clar, JIgnacio Ayestarán, Sandra Campos Fernández, Eva Forcadell-Ferreres, Immaculada Salvador-Adell, Neus Bofill, Berta Adell-Serrano, Josep Pedregosa Díaz, Núria Casacuberta-Barberà, Luis Urrelo-Cerrón, Àngels Piñol-Tena, Pablo Ryan Murúa, Covadonga Rodríguez Ruíz, Laura Carrión García, Juan ILazo Álvarez, Desire Macias Guerrero, Daniel Tognetti, Carlos García Redruello, David Mosquera Rodríguez, Eva María Menor Fernández, Sabela Vara Adrio, Vanesa Gómez Casal, Marta Segura Pensado, María Digna Rivas Vilas, Amaia García Sagastume, Raul de Pablo Sánchez, David Pestaña Laguna, Tommaso Bardi, Carmen Gómez Gonzalez, Maria Luisa Gascón Castillo, José Garnacho-Montero, Joan Ramon Masclans, Ana Salazar Degracia, Judit Bigas, Rosana Muñoz-Bermúdez, Clara Vilà-Vilardel, Francisco Parrilla, Irene Dot, Ana Zapatero, Yolanda Díaz, María Pilar Gracia, Purificación Pérez, Andrea Castellví, Cristina Climent, Lidia Serra, Laura Barbena, Iosune Cano, Alba Herraiz, Pilar Marcos, Laura Rodríguez, Maria Teresa Sariñena, Ana Sánchez, Juan Fernando Masa Jimenez, Gemma Gomà, Mercedes Ibarz, Diego De Mendoza, Victoria Alcaraz-Serrano, Joan Ramon Badia, Manuel Castella, Leticia Bueno, Catia Cillóniz, Pamela Conde, Javier Fernández, Karsa Kiarostami, Alexandre López-Gavín, Cecilia L Mantellini, Carla Speziale, Nil Vázquez, Hua Yang, Minlan Yang, Carlos Ferrando, Pedro Castro, Marta Arrieta, Jose Maria Nicolas, Rut Andrea, Marta Barroso, Sergio Álvarez, Dario Garcia-Gasulla, Adrián Tormos, Cesar Aldecoa, Rubén Herrán-Monge, José Ángel Berezo García, Pedro Enríquez Giraudo, Pablo Cardinal Fernández, Alberto Rubio López, Orville BáezPravia, Leire Pérez Bastida, Antonjo Alvarez Ruiz, Anna Parera Pous, Ana López Lago, Eva Saborido Paz, Patricia Barral Segade, Manuel Valledor Mendez, Luciano Aguilera, Esther López-Ramos, Ángela Leonor Ruiz-García, Belén Beteré, Rafael Blancas, Cristina Dólera, Gloria Perez Planelles, Enrique Marmol Peis, Maria Dolores Martinez Juan, Miriam Ruiz Miralles, Eva Perez Rubio, Maria Van der Hofstadt Martin-Montalvo, Tatiana Villada Warrington, Sara Guadalupe Moreno Cano, Federico Gordo, Basilisa Martinez Palacios, Maria Teresa Nieto, Sergio Ossa, Ana Ortega, Miguel Sanchez, Bitor Santacoloma, Introduction. COVID-19 severely impacted global health, especially older adults and those with comorbidities. Immunosuppressed patients are at high risk for severe outcomes, yet studies yield conflicting mortality rates for this group. This study examines the clinical characteristics and outcomes of immunosuppressed (IS) versus non-immunosuppressed (nIS) patients with COVID-19 in ICUs.MethodsA multicenter, observational case-control study included 5,824 ICU patients with COVID-19 from the CIBERESUCICOVID study. Patients were categorized as IS or nIS based on history of transplantation, HIV, active neoplasia, and use of immunosuppressive drugs or corticosteroids. The primary outcome was 90-day mortality; secondary outcomes included in-hospital, 15-day, 30-day and 1-year mortality, ICU-free days, ventilator-free days, and hospital length of stay. Subgroup analyses examined vaccination status and tocilizumab treatment. Propensity score (PS) matching was used to obtain balance among the baseline variables in the two groups.ResultsIS patients (n = 689, 11.8%) were older, had more comorbidities, and higher APACHE-II scores. After PS matching, IS patients had higher 90-day mortality (39 vs. 33%; HR 1.30, 95% CI 1.04 to 1.62), as well as higher in-hospital (37 vs. 29%; sHR 1.35, 95% CI 1.08 to 1.69), 30-day (28 vs 23%; HR 1.31, 95% CI 1.01 to 1.69) and 1-year mortality (45 vs. 38%; HR 1.26, 95% CI 1.02 to 1.57). Among IS patients, transplant recipients had significantly higher 90-day mortality after matching (HR 4.45, 95% CI 1.46 to 13.58). Vaccinated IS patients showed higher mortality than vaccinated nIS patients, though differences were not significant after PS matching. Tocilizumab treatment in IS patients was associated with reduced mortality; multivariable analysis confirmed a significant decrease in in-hospital mortality (sHR 0.56, 95% CI 0.42 to 0.76).ConclusionCritical immunosuppressed patients with COVID-19 have higher mortality, particularly transplant recipients. Tocilizumab shows potential benefits for IS patients. These findings highlight the need for tailored therapeutic strategies for immunosuppressed individuals with severe COVID-19. Further research is needed to confirm these results in the current clinical context., Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Centro de Investigación Biomédica en Red, Unión Española de Entidades Aseguradoras y Reaseguradoras, European Social Fund